15 Dec 2017
Board changes – Stephen Stamp appointed as CEO and Jan Petracek as COO

Dr Jan Petracek, aged 42, currently holds the following directorships and has held no other directorships in the past five years:

 

Current directorships: European Pharminvent Services s.r.o.

Pharminvent regulatory s.r.o.

PrimeVigilance d.o.o. Beograd-Novi Beograd

PrimeVigilance Inc.

PRIMEVIGILANCE LIMITED

PrimeVigilance Zagreb d.o.o.

SOUND OPINION LIMITED

 

Dr Jan Petracek holds 367,597 Ordinary Shares of 1 penny each in the Company.

Ergomed confirms that there are no further disclosures to be made in relation to Rule 17 of paragraph (g) of Schedule Two of the AIM Rules for Companies in respect of Dr Petracek’s appointment.

ENDS

Enquiries:

 

Ergomed plc Tel: +44 (0) 1483 503205
Peter George (Chairman)  
Stephen Stamp (Chief Executive Officer)  
   
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)  
James Black (Joint Broker)  
   
N+1 Singer Tel: +44 (0) 20 7496 3000
Alex Price (Joint Broker)  
   
Consilium Strategic Communications – for UK enquiries Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott

Ivar Milligan / Philippa Gardner

ergomed@consilium-comms.com
   
MC Services – for Continental European enquiries Tel: +49 211 5292 5222
Anne Hennecke  

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed’s fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.